Qian Yang

Qian Yang

Auto-generated profile, based on publicly available information

Qian Yang

Department of Hematology

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZDZhang Dongdong
Zhang Dongdong
ZLZiyi Luo
Ziyi Luo
YJYanxia Jin
Yanxia Jin
YCYanling Chen
Yanling Chen
TYTian Yang
Tian Yang
FZFuling Zhou
Fuling Zhou
Acute myeloid leukemia (AML) is a hematological malignancy with a poor prognosis attributed to elevated reactive oxygen species (ROS) levels. Thus, agents that inhibit ROS generation in AML should be exploited. Azelaic acid (AZA), a small molecular compound, can scavenge ROS and other free radicals, exerting antitumor effects on various tumor cells. Herein, this study evaluated the antileukemic activity of AZA against AML via regulation of the ROS signaling pathway. We found that AZA reduced intracellular ROS levels and increased total antioxidant capacity in AML cell lines and AML patient cells. AZA suppressed the proliferation of AML cell lines and AML patient cells, expending minimal cytotoxicity on healthy cells. Laser confocal microscopy showed that AZA-treated AML cells surged and ruptured gradually on microfluidic chips. Additionally, AZA promoted AML cell apoptosis and arrested the cell cycle at the G1 phase. Further analysis demonstrated that peroxiredoxin (Prdx) 2 and Prdx3 were upregulated in AZA-treated AML cells. In vivo, AZA prolonged survival and attenuated AML by decreasing CD33+ immunophenotyping in the bone marrow of a patient-derived xenograft AML model. Furthermore, mice in the AZA-treated group had an increased antioxidant capacity and Prdx2/Prdx3 upregulation. The findings indicate that AZA may be a potential agent against AML by regulating the Prdxs/ROS signaling pathway.

1 November 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ZTZelin Tian
Zelin Tian
JTJianing Tang
Jianing Tang
QYQian Yang
Qian Yang
XLXin Li
Xin Li
JZJian Zhu
Jian Zhu
GWGaosong Wu
Gaosong Wu
Breast cancer ranks first among female malignancies worldwide, and estrogen receptor-positive (ER+) breast cancer is the leading cause of cancer death in women. Abnormal oncogenic signaling has important effects on the development of breast cancer, such as ERα/ ESR1 (estrogen receptor alpha), PTEN (gene of phosphate and tension homology deleted on chromsome ten), NFκB(nuclear factor κB), and tumor protein p53 (p53 / TP53). SHARPIN is a ubiquitin-related protein that has important regulatory functions in inflammation control, immune organ development, and cancer development. SHARPIN is highly expressed in many cancers, especially in breast cancer. It plays an important role in controlling important carcinogenic pathways in breast cancer, such as p53 and ERα. This review emphasizes the functional role of SHARPIN and the recent advances in the molecular mechanisms by which SHARPIN regulates breast cancer development through ubiquitination.